Out of Specification results for active pharmaceutical ingredients (desogestrel and ethinyl estradiol) during stability testing at 30 months (expiry 36 months). Type I risk to health for patients who should not get pregnant, whether for medical reasons or exposure to agents detrimental to a developing fetus. Type II risk for the general population.
Depth of distribution
Patient level (pharmacies to contact their patients)